iBio, Inc Common Stock

Yahoo Finance • 2 months ago

iBio GAAP EPS of -$0.09

* iBio press release [https://seekingalpha.com/pr/20394853-ibio-reports-q2-fiscal-year-2026-financial-results-and-provides-corporate-update] (IBIO [https://seekingalpha.com/symbol/IBIO]): Q2 GAAP EPS of -$0.09. * iBio held cash, cash e... Full story

Yahoo Finance • 4 months ago

After-Hours Gainers: Exicure Tops List With 72% Jump, Wave Life And Assembly Biosciences Advance

(RTTNews) - Biotechnology stocks saw notable movement in after-hours trading on Monday, with several companies posting strong gains. Below is a structured look at the key movers and the developments driving their performance. Exicure, Inc... Full story

Yahoo Finance • 4 months ago

BC-Most Active Stocks

NEW YORK (AP) — prices for the Nasdaq composite, NYSE and NYSE American listed most active stocks. Nasdaq most active stocks: Stock Name Volume High Low Last Change Paranovus Entertain.Tech. Ltd. 852,838,067 0.0658 0.0476 0.05 +0.0134 Co... Full story

Yahoo Finance • 5 months ago

iBio to Participate in the 8th Annual Evercore Healthcare Conference

SAN DIEGO, Nov. 24, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), an AI-driven innovator of precision antibody therapies, today announced that it will participate in the 8th Annual Evercore Healthcare Conference, taking place Decem... Full story

Yahoo Finance • 5 months ago

iBio GAAP EPS of -$0.11, revenue of $0.1M beats by $0.07M

* iBio press release [https://seekingalpha.com/pr/20304986-ibio-reports-q1-fiscal-year-2026-financial-results-and-provides-corporate-update] (IBIO [https://seekingalpha.com/symbol/IBIO]): Q1 GAAP EPS of -$0.11. * Revenue of $0.1M beats... Full story

Yahoo Finance • 5 months ago

iBio Reports Q1 Fiscal Year 2026 Financial Results and Provides Corporate Update

Strengthened cash position and extended runway into the fourth quarter of fiscal year 2027 after closing underwritten public offering with up to potentially $100 million of total gross proceeds Presented non-human primate data for our pot... Full story

Yahoo Finance • 6 months ago

iBio to Present New Preclinical Data on Its Activin E Antibody at Two Upcoming Scientific Conferences, ObesityWeek® and PEGS Europe 2025

SAN DIEGO, Oct. 21, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ:IBIO), an AI-driven innovator of precision antibody therapies, today announced that Cory Schwartz, Ph.D., Director of Research and Early Development at iBio, will deliver an... Full story

Yahoo Finance • 7 months ago

Is it a Wise Move to Buy Liquidia Corp. (LQDA) Shares?

Arquitos Capital Management, an investment management firm, released its second-quarter 2025 investor letter. During the period, the fund delivered a net return of 13.1%, bringing year-to-date gains to an impressive 28.8% as of June 30, 20... Full story

Yahoo Finance • 7 months ago

iBio GAAP EPS of -$1.75, revenue of $0.4M beats by $0.2M

* iBio press release [https://seekingalpha.com/pr/20222653-ibio-reports-fiscal-year-2025-financial-results-and-provides-corporate-update] (NASDAQ:IBIO [https://seekingalpha.com/symbol/IBIO]): FY GAAP EPS of -$1.75. * Revenue of $0.4M (... Full story

Yahoo Finance • 7 months ago

iBio Reports Fiscal Year 2025 Financial Results and Provides Corporate Update

SAN DIEGO, Sept. 05, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ:IBIO), an AI-driven innovator of precision antibody therapies, today announced its financial results for the fiscal year ended June 30, 2025, and provided a corporate updat... Full story

Yahoo Finance • 8 months ago

IBio Prices $50 Mln Public Offering To Advance Preclinical Antibody Programs

(RTTNews) - iBio, Inc. (IBIO), an AI-driven developer of precision antibody therapies, has priced an underwritten public offering of pre-funded warrants for 71.54 million shares and accompanying Series G and Series H warrants, raising appr... Full story

Yahoo Finance • 8 months ago

iBio Announces Pricing of $50 Million Public Offering

SAN DIEGO, Aug. 19, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (Nasdaq: IBIO), an AI-driven innovator of precision antibody therapies, today announced the pricing of an underwritten public offering (the “offering”) of (i) pre-funded warrants to... Full story

Yahoo Finance • 8 months ago

Curious about the stocks that are showing activity after the closing bell on Monday?

The US market regular session of Monday is over, let's have a look at the top gainers and losers in the after hours session today. [postmarket] AFTER HOURS GAINERS TICKER CHANGE COMMENT LASE [https://www.chartmill.com/stock/q... Full story

Yahoo Finance • 8 months ago

iBio Announces Proposed Public Offering

SAN DIEGO, Aug. 18, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (Nasdaq: IBIO), an AI-driven innovator of precision antibody therapies, today announced it has commenced an underwritten public offering (the “offering”) of (i) pre-funded warrants... Full story

Yahoo Finance • 8 months ago

Impact Biomedical announces 3F US patent issue

* Impact Biomedical (NYSE:IBO [https://seekingalpha.com/symbol/IBO]) announced on Monday that the US Patent and Trademark Office has issued a patent titled “Composition and Method of Controlling Infectious Diseases with Functional Fragra... Full story

Yahoo Finance • 10 months ago

iBio and AstralBio Unveil Obesity Program with Novel Amylin Agonist Antibody Demonstrating Promising In Vivo Results

Lead amylin receptor agonist engineered antibody significantly reduced acute food intake in a mouse model of obesity, comparable to the efficacy of a leading amylin peptide agonist Findings support the potential of antibody-based agonists... Full story

Yahoo Finance • 10 months ago

iBio Presents Next-Generation Obesity and Cardiometabolic Pipeline Candidates on June 24 Conference Call

Review of promising Myostatin and Activin E antibody data iBio to announce 3rd target in Astral Bio Collaboration Conference call Tuesday, June 24 at 8:30 a.m. ET SAN DIEGO, June 23, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (Nasdaq: IBIO),... Full story

Yahoo Finance • 12 months ago

iBio Expands Cardiometabolic and Obesity Pipeline through Licensing of First-in-Class Antibody Targeting Activin E from AstralBio

SAN DIEGO, April 22, 2025 (GLOBE NEWSWIRE) -- Bio, Inc. (Nasdaq: IBIO), an AI-driven innovator of precision antibody therapies, today announced a licensing agreement with AstralBio Inc. for a preclinical first-in-class antibody targeting... Full story

Yahoo Finance • last year

iBio Announces IBIO-600 Non-Human Primate Data Showing Extended Half-Life and Muscle Growth, and Interim In Vivo Results for First-in-Class Activin E Antibody, Advancing Cardiometabolic and Obesity Pipeline

Non-human primate pharmacokinetics data suggests IBIO-600, a potentially best-in-class long-acting anti-myostatin antibody, could have a human half-life as long as 130 days Additional interim in vivo data for a first-in-class Activin E an... Full story

Yahoo Finance • last year

iBio, Inc. Common Stock (IBIO): Among Stocks Insiders Were Buying In Q1 2025

We recently published a list of 20 Stocks Insiders Were Buying In Q1 2025. In this article, we are going to take a look at where iBio, Inc. Common Stock (NASDAQ:IBIO) stands against other stocks insiders were buying in Q1 2025. About 30 m... Full story